Short Interest in Homology Medicines, Inc. (NASDAQ:FIXX) Drops By 14.2%

Posted by Defense World Staff on Jul 20th, 2023

Homology Medicines, Inc. (NASDAQ:FIXX – Get Free Report) was the target of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 261,800 shares, a decline of 14.2% from the June 15th total of 305,100 shares. Based on an average daily trading volume, of 116,100 shares, the short-interest ratio is currently 2.3 days. Approximately 0.6% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. FIX cut their price target on shares of Homology Medicines from $19.00 to $7.00 in a report on Thursday, April 6th. Chardan Capital reaffirmed a “buy” rating on shares of Homology Medicines in a research note on Monday, July 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.73.

Homology Medicines Stock Performance

Shares of FIXX stock opened at $1.00 on Thursday. The stock has a market cap of $57.79 million, a price-to-earnings ratio of -0.45 and a beta of -0.08. The firm has a fifty day moving average of $0.98 and a 200-day moving average of $1.17. Homology Medicines has a 52-week low of $0.80 and a 52-week high of $3.30.

Homology Medicines (NASDAQ:FIXX – Get Free Report) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. Homology Medicines had a negative net margin of 3,926.25% and a negative return on equity of 64.66%. The business had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.35 million. On average, sell-side analysts predict that Homology Medicines will post -1.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in Homology Medicines in the first quarter valued at approximately $51,000. BlackRock Inc. boosted its stake in Homology Medicines by 7.9% in the first quarter. BlackRock Inc. now owns 3,869,946 shares of the company’s stock valued at $11,765,000 after buying an additional 282,169 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Homology Medicines by 19.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 328,446 shares of the company’s stock valued at $998,000 after buying an additional 52,759 shares during the last quarter. Renaissance Technologies LLC grew its stake in Homology Medicines by 60.3% during the first quarter. Renaissance Technologies LLC now owns 234,000 shares of the company’s stock worth $711,000 after purchasing an additional 88,007 shares during the period. Finally, State Street Corp raised its holdings in shares of Homology Medicines by 17.1% during the first quarter. State Street Corp now owns 990,911 shares of the company’s stock valued at $3,012,000 after purchasing an additional 144,566 shares during the period. Institutional investors own 32.59% of the company’s stock.

About Homology Medicines

(Get Free Report)

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders.